These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1307 related articles for article (PubMed ID: 15686047)

  • 21. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy.
    Blystad AK; Delabie J; Kvaløy S; Holte H; Vålerhaugen H; Ikonomou I; Kvalheim G
    Br J Haematol; 2004 Jun; 125(5):605-12. PubMed ID: 15147376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
    Witzens-Harig M; Heilmann C; Hensel M; Kornacker M; Benner A; Haas R; Fruehauf S; Ho AD
    Stem Cells; 2007 Jan; 25(1):228-35. PubMed ID: 17204607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study.
    Decaudin D; Brousse N; Brice P; Haioun C; Bourhis JH; Morel P; Van Hoof A; Souleau B; Quesnel B; Gisselbrecht C
    Bone Marrow Transplant; 2000 Feb; 25(3):251-6. PubMed ID: 10673695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma.
    Stockerl-Goldstein KE; Horning SJ; Negrin RS; Chao NJ; Hu WW; Long GD; Hoppe RT; Amylon MD; Brown BW; Wong RM; Blume KG
    Biol Blood Marrow Transplant; 1996 May; 2(2):76-85. PubMed ID: 9118302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K; Margolin K; Champlin R; Forman S
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
    Scheid C; Pettengell R; Ghielmini M; Radford JA; Morgenstern GR; Stern PL; Crowther D
    Bone Marrow Transplant; 1995 Jun; 15(6):901-6. PubMed ID: 7581089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: A report from the Korean society of pediatric hematology-oncology.
    Won SC; Han JW; Kwon SY; Shin HY; Ahn HS; Hwang TJ; Yang WI; Lyu CJ
    Ann Hematol; 2006 Nov; 85(11):787-94. PubMed ID: 16932891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment results and prognostic significance of selected clinical and laboratory features in children diagnosed with malignant lymphoma].
    Kamieńska E
    Ann Acad Med Stetin; 1996; 42():105-22. PubMed ID: 9199116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
    Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
    J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.
    Phillips GL; Meisenberg BR; Reece DE; Adams VR; Badros AZ; Brunner JL; Fenton RG; Filicko J; Grosso DL; Hale GA; Howard DS; Johnson VP; Kniska A; Marshall KW; Mookerjee B; Nath R; Rapoport AP; Sarkodee-Adoo C; Takebe N; Vesole DH; Wagner JL; Flomenberg N
    Bone Marrow Transplant; 2004 Apr; 33(8):781-7. PubMed ID: 14767498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
    Cooney JP; Stiff PJ; Toor AA; Parthasarathy M
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):177-82. PubMed ID: 12652468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma.
    Wildes TM; Augustin KM; Sempek D; Zhang QJ; Vij R; Dipersio JF; Devine SM
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):840-6. PubMed ID: 18541205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
    Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
    Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients.
    Akhtar S; El Weshi A; Abdelsalam M; Hussaini H; Janabi I; Rahal M; Maghfoor I
    Bone Marrow Transplant; 2007 Oct; 40(7):651-8. PubMed ID: 17660837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The treatment results in children diagnosed with non-Hodgkin's lymphomas and acute B-cell lymphoblastic leukemias treated by the BFM protocols. The report of the POGM (Pediatric Oncology Group of Madrid)].
    Vivanco Martínez JL; López Pérez J; Melero Moreno C; Torres Valdivieso MJ; Palacios López ME; Contra Gómez T; Martín Ramos N; Bernacer Borja M; Gil López C; Valverde Moreno F
    An Esp Pediatr; 1998 Dec; 49(6):603-8. PubMed ID: 9972623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation.
    Demirer T; Ayli M; Fen T; Ozcan M; Arat M; Buyukberber S; Arslan O; Gurman G; Akan H; Ilhan O
    Bone Marrow Transplant; 2004 Nov; 34(9):781-6. PubMed ID: 15354206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
    Truelove E; Fox C; Robinson S; Pearce R; Perry J; Kirkland K; McQuaker G; Pagliuca A; Johnson P; Russell N; Cook G;
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):483-8. PubMed ID: 25490180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose therapy and autologous stem cell rescue for poor risk and refractory lymphoma: a single centre experience of 123 patients.
    Mahendra P; Johnson D; Hood IM; Scott MA; Barker P; Bass G; Jestice HK; Bloxham DM; Boraks P; Wimperis JZ; Baglin TP; Marcus RE
    Bone Marrow Transplant; 1996 Jun; 17(6):973-8. PubMed ID: 8807102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 66.